Research programme: endothelin B receptor antagonists - ENB Therapeutics

Drug Profile

Research programme: endothelin B receptor antagonists - ENB Therapeutics

Alternative Names: ENB 001; ENB 002; ETBR blocker - ENB Therapeutics

Latest Information Update: 01 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ENB Therapeutics
  • Class Small molecules
  • Mechanism of Action Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioblastoma; Head and neck cancer; Malignant melanoma

Most Recent Events

  • 25 Apr 2016 Preclinical trials in Glioblastoma in USA (SC)
  • 25 Apr 2016 Preclinical trials in Head and neck cancer in USA (SC)
  • 25 Apr 2016 ENB Therapeutics enters into a partnership with an undisclosed company for nanoparticle intranasal drug delivery system
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top